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Benoit Daneault, MD, Elana Koss, MD, Tamim M. Nazif, MD, Martin B. Leon, MD,
Mathew R. Williams, MD
New York, New YorkAn 85-year-old man was recently admitted to our
institution with congestive heart failure (New York
Heart Association functional class III/IV) and
hemolytic anemia. The patient had a prior history
of Streptococcus viridans bacterial endocarditis that
resulted in severe aortic and mitral regurgitations.
In 2002, he underwent surgical aortic (Carpentier-
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Figure 1. TEE Showing the Mitral Bioprosthetic Valve
Transesophageal echocardiogram (TEE) demonstrating (A) color Do
mitral regurgitation caused by a ﬂail leaﬂet generates an eccentric
was calculated to be 0.42 cm2. (B) Measurements of the internal d
tion imaging.Manuscript received July 3, 2012; accepted July 19, 2012.Edwards #25, Edwards Lifesciences, Irvine, Cali-
fornia) and mitral (Hancock modified #29,
Medtronic, Minneapolis, Minnesota) valve re-
placements. Transesophageal echocardiogram
(TEE) performed during the recent hospitalization
showed that the left ventricular ejection fraction
was 55%. The Hancock modified bioprosthesis in
the mitral position was well seated, but there was
severe mitral regurgitation caused by a flail leaflet
(Fig. 1A, Online Video 1). The mitral bioprosthe-
sis was oval-shaped, and the internal diameters
were measured to be 21  23.8 mm (Fig. 1B). In
addition, there was severe stenosis of the Carpentier-
Edwards valve in the aortic position with an aortic
valve area (AVA) of only 0.9 cm2. On 3-dimensional
TEE, the internal diameter of the valve was mea-
through the mitral bioprosthetic valve. Severe intraprosthetic
gitant jet (see Online Video 1). The effective regurgitant oriﬁce
ions of the mitral bioprosthesis using 3-dimensional reconstruc-ppler
regur
imenssured to be 24 mm (Fig. 2).
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95Figure 2. TEE Showing the Aortic Bioprosthetic ValveTransesophageal echocardiogram (TEE) showing (A) planimetry of the oriﬁce and (B) measurement of the internal diameter of the aortic bioprosthesis.Figure 3. The 4 Prosthetic Heart Valves
Final ﬂuoroscopic images showing the 4 prosthetic heart valves (Hancock modiﬁed, Carpentier-Edwards, and 2 Edwards SAPIEN transcatheter heart valves) in dif-
ferent angulations.
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Concomitant Double Valve-In-Valve Replacements
96On the basis of his clinical presentation and the TEE
findings, the patient was felt to require reoperative aortic
and mitral valve replacements. He was evaluated by 2
cardiothoracic surgeons and judged to be inoperable on the
basis of his advanced age, frailty, multiple comorbidities,
and the complexity of the proposed surgery. Therefore, it
was decided to proceed with transapical, transcatheter,
double valve-in-valve implantation using 2 commercially
available RetroFlex 3 transfemoral devices (Edwards Life-
sciences, Irvine, California). In the hybrid operating room,
without pre-dilation but under rapid ventricular pacing, a
26-mm Edwards SAPIEN transcatheter heart valve (THV)
was first deployed within the Carpentier-Edwards valve in the
aortic position (Online Video 2). With a 2-step inflation
technique, an Edwards SAPIEN 26-mm THV was then
deployed within the Hancock modified bioprosthesis in
the mitral position (Online Video 3). TEE after deploy-
ment of both valves showed excellent function of the newaortic prosthetic valve with an AVA of 2.08 cm2, peak and
mean gradients of 12 and 6 mm Hg, respectively, and no
significant aortic insufficiency. Moreover, there was only
trace residual mitral regurgitation, and no significant steno-
sis (mitral valve area 1.65 cm2).
To our knowledge, this case represents the first concom-
itant transcatheter double valve-in-valve replacements per-
formed in theUnited States (Fig. 3, Online Videos 4, 5, 6, and 7).
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APPENDIX
For supplementary videos and their legends, please see the online version
of this paper.
